Evaluation of cardiac biomarker elevation after percutaneous coronary intervention or coronary artery bypass graft
- Conditions
- Patients with multivessel coronary artery disease and stable angina with formal indication for revascularization proceduresCirculatory SystemAngina pectoris, unspecified
- Registration Number
- ISRCTN09454308
- Lead Sponsor
- Zerbini Foundation [Fundação Zerbini] (Brazil)
- Brief Summary
2016 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26912303 results 2017 Results article in http://www.ncbi.nlm.nih.gov/pubmed/29201152 results 2017 Results article in http://www.ncbi.nlm.nih.gov/pubmed/29284532 results 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/33280019/ results (added 07/12/2020) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38982515/ subanalysis in patients with stable coronary artery disease with and without type 2 diabetes (added 16/07/2024)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 155
1. Stable angina
2. Multi-vessel coronary artery disease
3. Preserved left ventricular function
4. Formal indication to revascularization procedures (PCI or CABG)
1. Recent myocardial infarction (=6 months)
2. Signs of manifest or suspected infections
3. Rheumatologic disease activity
4. Chronic renal failure (creatinine level >2.0mg/dL)
5. Recent (= 6 months) pulmonary embolism or venous thromboembolism
6. Does not sign the consent form
7. Contraindication for the use of glycoprotein IIb/IIIa inhibitors
8. Cardiac magnetic resonance (CMR) examination, for example, a person with a pacemaker or severe claustrophobia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall death in a 5-year follow-up
- Secondary Outcome Measures
Name Time Method 1. Levels of CK-MB isoenzyme and I-Troponin in association with presence of myocardial fibrosis <br>2. Left ventricle ejection disfunction assessed by CMR